Transcriptome-wide expression analysis of pooled brain samples of patients with Alzheimer's disease compared to controls

Brain tissue of 3 patients with Alzheimer's disease (AD) and 3 healthy controls dying without any history of neurological or psychiatric illness was used. The diagnosis of AD was made on the basis of both clinical and neuropathological evidence according to the criteria of the International Working Group (IWG) for New Research Criteria for the diagnosis of AD in the revision of 2014 (IWG-2),16 the NIA-AA diagnostic criteria in the revision of 201117 and the NIA-AA guidelines for the neuropathological assessment of AD. Only cases with typical AD according to IWG-2 criteria were included. Transcriptome-wide expression of AD and healthy control samples was assessed with Affymetrix Human Whole Genome Tiling Array 1.0 Set. Equal masses of total RNA derived from three patients with Alzheimer's disease and three control samples, respectively, were pooled. For each pool the Affymetrix Human Whole Genome Tiling Array 1.0 Set consisting of 14 arrays was used to assess transcriptome-wide expression.